India, May 18 -- Co-Diagnostics Inc. (CODX), a molecular diagnostics company, on Thursday reported first quarter results, and provided various business updates.
Q1 2026:
The company reported a net loss of $9.14 million amounting to $4.06 per share, while in the first quarter of 2025 it reported a net loss of $7.53 million, or $7.05 per share.
The net loss resulted due to a higher cost of revenue amounting to $0.19 million, compared to $0.02 million in the prior year. Additional contributors to the loss include expenditure on research and development, clinical studies, and lower other income.
Revenues reached $0.14 million, a mild increase from the $0.05 million recorded a year ago. Product revenues accounted entirely for the total recor...